Types of cancers and observed/expected ratio in the NCI IBMFS DC cohort
| Cancer . | Age, y . | Observed . | Expected . | O/E . | 95% CI . |
|---|---|---|---|---|---|
| All sites, median (range) | 37 (25-44) | 7* | 0.6 | 11† | 4-23 |
| All solid tumors, median (range) | 37 (25-42) | 5* | 0.5 | 8† | 2-20 |
| Tongue | 25, 25, 42 | 3 | 0 | 1154† | 232-3372 |
| AML | 28, 44 | 2 | 0.01 | 196† | 22-707 |
| Cervical SCC | 37 | 1 | 0.02 | 43 | 0.6-236 |
| Lymphoma, non-Hodgkin | 42 | 1 | 0.03 | 34 | 0.5-191 |
| Basal cell carcinoma, face | 29 | 1* | NA | NA | NA |
| MDS, median (range) | 35 (19-61) | 5 | 0 | 2663† | 858-6215 |
| Cancer . | Age, y . | Observed . | Expected . | O/E . | 95% CI . |
|---|---|---|---|---|---|
| All sites, median (range) | 37 (25-44) | 7* | 0.6 | 11† | 4-23 |
| All solid tumors, median (range) | 37 (25-42) | 5* | 0.5 | 8† | 2-20 |
| Tongue | 25, 25, 42 | 3 | 0 | 1154† | 232-3372 |
| AML | 28, 44 | 2 | 0.01 | 196† | 22-707 |
| Cervical SCC | 37 | 1 | 0.02 | 43 | 0.6-236 |
| Lymphoma, non-Hodgkin | 42 | 1 | 0.03 | 34 | 0.5-191 |
| Basal cell carcinoma, face | 29 | 1* | NA | NA | NA |
| MDS, median (range) | 35 (19-61) | 5 | 0 | 2663† | 858-6215 |
For all cancer types other than MDS, expected cancer incidences were calculated from SEER 9 Registry rates 1973-2005 for white/black/other. Time at risk before 1973 used 1973-1974 rates, and time at risk after 2005 used 2000-2005 rates. For MDS, expected rates were calculated from SEER 9 Registry rates for 2001-2005.9
NA indicates not available.
Basal cell carcinoma case was not included in O/E because SEER does not track nonmelanoma skin cancer and not included in solid tumors because it followed BMT.
P < .05 that the true O/E ratio equals 1.0 (exact 2-sided tests).